Ece KONAÇ, Muzaffer EROĞLU, H İlke ÖNEN, Abdullah EMEKCİ

Angiopoietin-2 gene polymorphisim in sporadic prostate cancer

Amaç: Anjiyogenezis, prostat kanserinin lokal ilerleyişi ve metastazında kritik bir role sahiptir. Anjiyogenezise bağımlı genlerde meydana gelen tek nükletit polimorfizmleri, kanserin oluşum ve ilerleme derecesini etkilemektedirler. Anjiyopoietin-2 (ANGPT-2), vasküler büyüme ve regresyonun en önemli düzenleyicilerinden olmakla beraber, prostat ve prostat tümörlerindeki rolü bilinmemektedir. ANGPT-2’de var olan DNA sekans varyasyonları, genlerin ürünlerini veya aktivitelerini değiştirebilirler. Bu çalışmada ANGPT-2 exon 4 G/A’da meydana gelen değişimlerin Türk popülasyonunda sporadik prostat kanser hastalarını nasıl etkilediğini belirlemeyi amaçladık. Gereç ve Yöntemler: 52 sporadik prostat kanser hastası ve 52 sağlıklı kontrolü kapsayan hasta kontrol çalışması yapılmıştır. Farklı ANGPT-2 alellerini tanımlamak amacıyla, Polimeraz Zincir Reaksiyonu (PCR) ve Restriksiyon Parçacık Uzunluk Polimorfizmi (RFLP) yöntemleri uygulanmıştır. Bulgular: Polimorfizme ait genotip ve alel frekans dağılımları hastalar ve kontrol grubu arasında istatistiksel olarak anlamlı bir farklılığa işaret etmemiştir (P>0.05). Ayrıca, hastaların tümör lenf nodu metastazı (TNM), Gleason skoru (GS) ve serum prostat-spesifik antijeni (PSA) seviyelerine göre sınıflandırılması, ANGPT-2 exon 4 G/A genotipleri arasında anlamlı farklılıklar göstermemiştir (P>0.05). Sonuç: Bu çalışma, sporadik prostat kanseri hastalarında ANGPT-2 exon 4 G/A polimorfizmi üzerine yapılan ve bu polimorfizmin Türk popülasyonunda prostat kanseri ile ilişkili olmadığını gösteren ilk çalışmadır.

Sporadik prostat kanserinde anjiyopoietin-2 gen polimorfizmi

Purpose: Angiogenesis is a critical requirement for local proliferation and metastasis of prostate cancer. Single nucleotide polymorphisms in angiogenesis-dependent genes affect the degree of cancer development and progression. Angiopoietin-2 (ANGPT-2) is one of the principal regulators of vascular growth and regression; however, its role in normal prostate and prostate tumors is largely unknown. DNA sequence variations in ANGPT-2 may alter the production outcomes or activities of the genes. In this study, we aimed to determine how the changes in the ANGPT-2 exon 4 G/A affect sporadic prostate cancer patients in the Turkish population. Materials and Methods: A case-control study on 52 sporadic prostate cancer patients and 52 healthy control subjects was conducted. Polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analyses were performed to identify different ANGPT-2 alleles. Results: The distribution of genotype and allele frequencies of the polymorphism did not yield a statistically significant difference between patients and controls (P>0.05). Furthermore, classification of patients by tumor, lymph nodes, metastasis (TNM), Gleason scores (GS), and serum prostatespecific antigen (PSA) levels showed no significant differences among the ANGPT-2 exon 4 G/A genotypes (P>0.05). Conclusion: This is the first report on the ANGPT-2 exon 4 G/A polymorphism in patients with sporadic prostate cancer demonstrating that the investigated polymorphism is not associated with prostate cancer in the Turkish population.

PDF

___

1. Cancel-Tassin G, Cussenot O. Prostate cancer genetics. Minerva Urol Nefrol 2005; 57: 289-300.
2. Hsieh CC, Thanos A, Mitropoulos D, Deliveliotis C, Mantzoros CS, Trichopoulos D. Risk factors for prostate cancer: a case-control study in Greece. Int J Cancer 1999; 80: 699-703.
3. Singh R, Eeles RA, Durocher F, et al. High risk genes predisposing to prostate cancer development - do they exist? Prostate Cancer Prostatic Dis 2000; 3: 241-247.
4. Bott SR, Arya M, Shergill IS, Williamson M. Molecular changes in prostatic cancer. Surg Oncol 2005; 14: 91-104.
5. Murata M, Watanabe M, Yamanaka M, et al. Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett 2001; 165: 171-177.
6. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002; 52: 213-235.
7. Costa S, Pinto D, Morais A, et al. Acetylation genotype and the genetic susceptibility to prostate cancer in a southern European population. Prostate 2005; 64: 246-252.
8. Giwercman YL, Abrahamsson PA, Giwercman A, Gadaleanu V, Ahlgren G. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population. Eur Urol 2005; 48: 679-685.
9. John EM, Schwartz GG, Koo J, Van Den Berg D, Ingles SA. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res 2005; 65: 5470-5479.
10. Komiya Y, Tsukino H, Nakao H, Kuroda Y, Imai H, Katoh T. Human glutathione S-transferase A1, T1, M1, and P1 polymorphisms and susceptibility to prostate cancer in the Japanese population. J Cancer Res Clin Oncol 2005; 131: 238-242.
11. Tigli H, Yazici H, Dalay N. Cyp17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia. Res Commun Mol Pathol Pharmacol 2003; 113-114: 307-314.
12. Aktas D, Hascicek M, Sozen S, Ozen H, Tuncbilek E. CYP1A1 and GSTM1 polymorphic genotypes in patients with prostate cancer in a Turkish population. Cancer Genet Cytogenet 2004; 154: 81-85.
13. Silig Y, Pinarbasi H, Gunes S, Ayan S, Bagci H, Cetinkaya O. Polymorphisms of CYP1A1, GSTM1, GSTT1, and prostate cancer risk in Turkish population. Cancer Invest 2006; 24: 41-45.
14. Saaristo A, Karpanen T, Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 2000; 19: 6122-6129.
15. Borre M, Offersen BV, Nerstrom B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998; 78: 940-944.
16. Lissbrant IF, Lissbrant E, Damber JE, Bergh A. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 2001; 35: 437-542.
17. Nicholson B, Theodorescu D. Angiogenesis and prostate cancer tumor growth. J Cell Biochem 2004; 91: 125-150.
18. Ward EG, Grosios K, Markham AF, Jones PF. Genomic structures of the human angiopoietins show polymorphism in angiopoietin-2. Cytogenet Cell Genet 2001; 94: 147-154.
19. Zhang L, Yang N, Park JW, et al. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 2003; 63: 3403-3412.
20. McCarron SL, Edwards S, Evans PR, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002; 62: 3369-3372.
21. Caine GJ, Blann AD, Stonelake PS, Ryan P, Lip GY. Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1. Eur J Clin Invest 2003; 33: 883-890.
22. Lin CC, Wu HC, Tsai FJ, Chen HY, Chen WC. Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer. Urology 2003; 62: 374-377.
23. Soulitzis N, Karyotis I, Delakas D, Spandidos DA. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol 2006; 29: 305-314.
24. Stanford PM, Halliday GM, Brooks WS, et al. Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations. Brain 2000; 123: 880-893.
25. Pietrowski D, Tempfer C, Bettendorf H, et al. Angiopoietin-2 polymorphism in women with idiopathic recurrent miscarriage. Fertil Steril 2003; 80: 1026-1029.
26. Wurmbach JH, Hammerer P, Sevinc S, Huland H, Ergun S. The expression of angiopoietins and their receptor Tie-2 in human prostate carcinoma. Anticancer Res 2000; 20: 5217-5220.
27. Richard C, Kim G, Koikawa Y, et al. Androgens modulate the balance between VEGF and angiopoietin expression in prostate epithelial and smooth muscle cells. Prostate 2002; 50: 83-91.
28. Lind AJ, Wikstrom P, Granfors T, Egevad L, Stattin P, Bergh A. Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer. Prostate 2005; 62: 394-399.
29. Tait CR, Jones PF. Angiopoietins in tumours: the angiogenic switch. J Pathol 2004; 204: 1-10.
30. Huber A, Grimm C, Pietrowski D, et al. An angiopoietin-2 gene polymorphism in unexplained intrauterin fetal death: a multi-center study. J Reprod Immunol 2005; 65: 47-53.
31. Denschlag D, Bettendorf H, Watermann D, Keck C, Tempfer C, Pietrowski D. Polymorphism of the p53 tumor suppressor gene is associated with susceptibility to uterine leiomyoma. Fertil Steril 2005; 84: 162-166.
32. Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP. American Joint Committee Cancer Staging Manual, 5th edition. Philadelphia: Lippincott-Raven, 1997, p. 219-224.
33. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992; 23: 273-279.
34. Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 1997; 157: 2040-2041.
35. Jones A, Fujiyama C. Angiogenesis in urological malignancy: prognostic indicator and therapeutic target. BJU Int 1999; 83: 535-555.
36. Yang HP, Woodson K, Taylor PR, et al. Genetic variation in interleukin 8 and its receptor genes and its influence on the risk and prognosis of prostate cancer among Finnish men in a large cancer prevention trial. Eur J Cancer Prev 2006; 15: 249-253.
37. Panguluri RC, Long LO, Chen W, et al. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 2004; 25: 961-966.
38. Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, Novario R. Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 2002; 5: 123-127.